Report, Stock No. 017–001–00474–0) or ''Healthy People 2000'' (Summary Report, Stock No. 017–001–00473–1) referenced in the ''INTRODUCTION'' through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325, telephone (202) 512–1800.

Dated: January 27, 1998.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–2571 Filed 2–2–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Revised Diphtheria, Tetanus, and Pertussis (DTD/DTaP/DT) Vaccine Information Materials; Amendment

A notice published in the **Federal Register** on January 9, 1998, [63 FR 1730]. The notice is amended as follows:

On page 1733, first column, under number 9. After ''Visit the CDC website at http://www.cdc.gov/nip'' line and before ''DTP/DTaP/DT***'' add the following:

U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
National Immunization Program

All other information and requirements of the January 9, 1998, notice remain the same.

Dated: June 27, 1998.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–2570 Filed 2–2–98; 8:45 am]

BILLING CODE 4163–18–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Anti-Infective Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Anti-Infective Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on February 19, 1998, 8 a.m. to 5 p.m., and on February 20, 1998, 8:30 a.m. to 2 p.m.

Location: Gaithersburg Hilton, Ballroom, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Ermona B. McGoodwin or Danyiel A. D'Antonio, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12530. Please call the Information Line for up-to-date information on this meeting.

Agenda: On February 19, 1998, the committee will discuss new drug applications (NDA's) 50–747 and 50–748 quinupristin/dalfopristin (Synercid®, Rhone-Poulenc Rorer Pharmaceuticals, Inc.) for use in the treatment of vancomycin-resistant *Enterococcus faecium* (VREF) infections, complicated skin and skin structure infections, community-acquired pneumonia, and hospital-acquired (nosocomial) pneumonia. On February 20, 1998, the committee will meet in closed session to permit discussion and review of trade secret and/or confidential information.

Procedure: On February 19, 1998, from 8 a.m. to 5 p.m. the meeting will be open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 13, 1998. Oral presentations from the public will be scheduled between approximately 1:30 p.m. and 2:30 p.m. on February 19, 1998. Time allotted for each presentation may be limited. Those desiring to make formal presentations should notify the contact person before February 13, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On February 20, 1998, from 8:30 a.m. to 2 p.m. the meeting will be closed to permit discussion and review of trade secret and/or confidential information. (5 U.S.C. 552b(c)(4)). The investigational new drug (IND) and Phase I and II drug products in process will be presented.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 27, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–2577 Filed 2–2–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Drug Abuse Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Drug Abuse Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on February 19, 1998, 8:30 a.m. to 5:30 p.m.

Location: Holiday Inn, Versailles Ballrooms III and IV, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Karen M. Templeton-Somers, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4090, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12535. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will discuss the scientific evidence for initiating a scheduling action for ULTRAM® (tramadol hydrochloride), R. W. Johnson Pharmaceutical Research Institute, under the Controlled Substances Act. The committee will also evaluate the effectiveness of the independent steering committee in detecting, moderating, and preventing the physical dependence and abuse of ULTRAM® and make suggestions for improving the surveillance of its misuse.

Procedure: On February 19, 1998, from 8:30 a.m. to 3:45 p.m., the meeting is open to the public. Interested persons may present data, information, or views,

orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 11, 1998. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 11, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On February 19, 1998, from 3:45 p.m. to 5:30 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). The investigational new drug and Phase I and II drug products in process will be presented and recent action on selected new drug applications will be discussed.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 27, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–2576 Filed 2–2–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Pseudomonas Exotoxin A-Like Chimeric Immunogens

David J. Fitzgerald (NCI)

Serial No. 60.052,375 filed 11 Jul 97 (Assignee: United States Government)

Licensing Contact: Robert Benson, 301/496–7056 ext. 267

This invention concerns a recombinantly made chimeric immunogen comprising a non-toxic version of Pseudomonas exotoxin A (PE) in which the Ib domain is replaced with a non-native epitope. This immunogen can be used as a vaccine, either as a protein or as DNA, and can elicit humoral, cell-medicated and secretory immune responses against the non-native epitope. The non-native epitope fits into the cysteine-cysteine loop of the Ib domain, thus epitopes normally part of a loop are held in their natural conformation. Chimeric immunogens comprising the V3 loop of the HIV–1 env protein have been shown to raise, in rabbits, neutralizing antibodies against clinical isolates of HIV, some cross-protection was seen. Anti-V3 IgA antibodies were raised upon mucosal administration. The claims cover: (a) Chimeric immunogens, (b) nucleic acids encoding chimeric immunogens, (c) antibodies raised against chimeric immunogens, (d) vaccines and methods of immunization.

Pseudomonas Exotoxin A-Like Chimeric Immunogens for Mucosal Immunity

David J. Fitzgerald (NCI) and Randall J. Mrsny (Genentech Corp.)

Serial No. 60/056,924 filed 11 Jul 97 (Assignees: United States Government and Genentech Corporation)

Licensing Contact: Robert Benson, 301/496–7056 ext. 267

This invention claims the use of the chimeric immunogens claimed in 60/052,375 to elicit a secretory IgA–medicated immune response. The inventors have shown that parenteral and mucosal administration of the HIV V3 loop/Exotoxin A chimeric immunogen to rabbits raises both a humoral and cell-medicated immune response against HIV. Both parenteral and mucosal administration result in IgG and IgA antibodies being raised, mucosal administration resulted in higher IgA production. Compositions comprising secretory IgA reactive with the non-native epitope are also claimed.

Pin*Point—A Method To Determine Transcription Factor Binding Site In Vivo

Jay Chung (NHLBI)

Serial Nos. 08/826,622 and 08/825,664 filed 03 Apr 97

Licensing Contact: Joseph Contrera, 301/496–7056 ext. 244

Transcription factors play central roles in many disease processes: cancer, AIDS, developmental aberrations, aging and obesity, just to name a few. Therefore, understanding these disease processes and finding cures for them will be greatly assisted by the capability to determine the genes targeted by the transcription factors in vivo. Toward this end, we have designed an in vivo method PIN*POINT) ProteIN POsition Identification with Nuclease Tail). In this method, a fusion protein composed of a chosen protein linked to a non-sequence specific nuclease is expressed in vivo and the binding of the protein to DNA is made detectable by the nuclease-induced cleavage near the binding site. For example, p53-nuclease fusion protein expressed in vivo will bind to the p53 binding site and mark it by cleaving the DNA near it. The cleavage site can be identified by a number of techniques currently available. A mammalian expression vector designed to express a fusion protein consisting of a polypeptide of one's choice and the nuclease is available as are expression vectors for Sp1 nuclease, TBP (TATA binding protein)-nuclease (for identifying promoters of genes) and other transcription factors. PIN*POINT is described in a paper soon to be published by Lee et al., (1998) PNAS 95, 060–974.

Dated: January 23, 1998.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 98–2561 Filed 2–2–98; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Heart, Lung, and Blood Institute Special Emphasis Panel (SEP) meeting: